Month: May 2025

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their positionJERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a potential step-down antifungal therapy following IV echinocandin for invasive candidiasis, a life-threatening infection. The study had been...

Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company’s Board of Directors, effective May 22, 2025. “We are delighted to welcome Dr. Carr-Brendel to Glucotrack’s Board of Directors,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board...

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “company”) (TSX, NYSE: HBM), announced today that the Toronto Stock Exchange (the “TSX”) has approved its notice of intention to commence a normal course issuer bid (“NCIB”) for its common shares (“Shares”). The NCIB will be made in accordance with the requirements of the Toronto Stock Exchange and applicable securities laws. Pursuant to the NCIB, Hudbay is authorized to acquire up to a maximum of 19,751,983 Shares, representing 5% of its issued and outstanding Shares as of May 22, 2025, for cancellation over a 12-month period. The actual number of Shares which may be purchased by Hudbay pursuant to the NCIB and the timing of such purchases will be determined by management of the Company and remains subject to a number of factors, including market conditions,...

Company announcementfor ROCKWOOL A/SRelease no. 34 – 2025to Nasdaq Copenhagen         28 May 2025 Total number of voting rights and share capital in ROCKWOOL A/S On 2 May 2025, ROCKWOOL A/S (“the Company”) completed a reduction of its share capital by nominally 4,601,300 DKK. The reduction was carried out by cancellation of treasury B shares in accordance with the resolution adopted at the Company’s Annual General Meeting on 2 April 2025. In accordance with Section 32 of the Danish Capital Market Act, the Company is required to disclose the total number of voting rights and shares in the event of changes. Following completion and registration of the capital reduction, the Company’s share capital and total number of voting rights are as follows:  Share capital (nominal value, DKK) Number of shares (of 1 DKK each) Number of votesClass...

RESTON, Va., May 28, 2025 (GLOBE NEWSWIRE) — Comscore, Inc. (NASDAQ: SCOR), a global leader in measuring and analyzing consumer behavior, today announced an expansion of its partnership with Yahoo DSP, adding Comscore’s AI powered ID-free audiences to Yahoo’s existing suite of targeting solutions. As third-party signals continue to disappear and the media industry braces for the next wave of privacy regulation, these AI-powered audiences offer a privacy-centric approach for reaching consumers without relying on traditional identifiers, building on the trusted contextual segments and brand safety audiences already available in the buy-side platform. This is particularly impactful for highly regulated industries, such as health, pharma, and financial services. Through this integration, Yahoo DSP clients can now activate Comscore’s...

Coverage marks SeaStar Medical’s second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered annually DENVER, May 28, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has agreed to pay for certain expenses incurred by medical centers treating patients covered by Medicare or Medicaid who are enrolled in the NEUTRALIZE-CRS investigational clinical trial. This follows the company’s first award for reimbursement by the CMS that was granted in July 2024 for qualified...